Kornimate/medical-research-clean huggingface dataset:
effects of zoledronic acid versus alendronate on bone loss after kidney and kidney/pancreas transplants

Conditions: Renal Insufficiency

Summary: the study is designed to look at the effect of different bone treatment plans on bone loss after kidney or kidney/pancreas transplant.

the aims are to determine baseline bone mineral density (bmd) in kidney and kidney/pancreas transplant patients who will be randomized to weekly alendronate, annual zoledronic acid infusions or placebo (calcium with vitamin d). these patients will be followed for two years with annual bone density testing as well as biochemical markers. a secondary aim is to evaluate the compliance.

Eligibility criteria:
inclusion criteria: * transplant patients who have had a kidney or kidney/pancreas transplant in the last 150 days with adequate kidney function as defined by a calculated creatine clearance of 35ml/min or more and serum creatinine less than 3.0 exclusion criteria: * dual x-ray absorptiometry (dxa) t-score at the spine or hip of -3 or lower * history of more than one vertebral or non-vertebral fracture in the past two years * abnormalities of the esophagus which delay esophageal emptying * inability to stay upright for 30 minutes * pregnant, nursing women or women not using an effective form of birth control * hypocalcemia * hypercalcemia * calculated creatinine clearance of \ 3.0 * patients already treated with bisphosphonates within the past one year * patients unable to undergo dxa * patients with cancer

Keywords: bone density osteopenia transplant zoledronic acid alendronate
molecular profiling of advanced biliary tract cancers

Conditions: Biliary Tract Cancer

Summary: this is a study where fresh tumor tissue and blood samples will be collected from patients with advanced biliary tract cancer who will be undergoing 1st line therapy with gemcitabine or fluorouracil (5-fu) regimens to see how useful it is to look for changes and characteristics in genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour to find characteristics that may be useful in choosing treatments for patients in the future.

changes (mutations) in genes have been shown to be an important characteristic in cancers. looking at differences in genes in patients with unresectable or metastatic biliary tract cancer and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment.

Eligibility criteria:
inclusion criteria: * patients must have a histological or radiological diagnosis of inoperable or metastatic biliary tract cancer (btc). * patient must have a tumor lesion that is amenable to a core needle biopsy as judged by a staff radiologist. * patients must have a measurable lesion by recist 1.1 in addition to the lesion that is going to be biopsied. * patients must be fit enough to safely undergo a tumor biopsy as judged by the investigator. * eastern cooperative group (ecog) performance status ≤ 1 (karnofsky ≥60%). * life expectancy of greater than 90 days, as judged by the investigator. * within 14 days of the proposed biopsy date, patients must have normal organ and marrow function. * patients must undergo systemic treatment with gemcitabine or 5-fu based regimens as first line standard systemic palliative treatment with or without other investigational agents within a clinical trial. * ability to understand and willing to sign a written informed consent document. exclusion criteria: * patients with one or more contraindications to tumor biopsy. * patients who have had prior systemic treatment (chemotherapy or any other anti-cancer agent) in the advanced setting. * patients who are currently on anti-cancer treatment including chemotherapy. * patients with known brain metastases are excluded from participation in this clinical study. * uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures
point-of-care ultraviolet microscopy for cervical cancer screening

Conditions: Cervical Cancer

Summary: this study aims to determine the image features of cervical cells, as measured via ultraviolet microscopy, that would constitute a positive screening and a negative screening result for cervical dysplasia, a precursor to cervical cancer, as measured against liquid-based papanicolaou testing.

the study population will consist of patients presenting to one of the three outpatient gynecology clinics within the banner university medical center system for either a routine or follow up cervical cancer screening. eligible subjects will be informed of the study and asked to consent to participate in accordance with standard informed consent protocol. the subject will undergo a papanicolaou screening test, using both a spatula and a cytobrush and collected in a thinprep specimen container according to the manufacturer's instructions. this specimen will be used for standard-of-care cytology. a second specimen will then be obtained in an identical fashion, labeled with a deidentified code unique to the subject, and held under refrigeration pending microscopy. the second specimen will be taken from the clinic for processing in preparation for uv microscopy. a sample of the specimen will be smeared onto a uv slide and images taken. the uv images will be then analyzed to extract the following features for determining the stage of cervical lesion: * cellularity: the density of cells in the sample. a high cellularity indicates an abnormal growth of cells. * nuclear features: the size and shape of the nuclei in the cells. abnormal nuclear features, such as enlarged nuclei or irregular chromatin distribution, can indicate the presence of a cervical lesion. * cytoplasmic features: the appearance of the cytoplasm in the cells. abnormal cytoplasmic features, such as vacuolation or hyperchromasia, can indicate the presence of a cervical lesion. * cellular architecture: the organization and arrangement of the cells in the sample. abnormal cellular architecture, such as loss of polarity or crowding of cells, can indicate the presence of a cervical lesion. a second subject arm will consist of patients presenting to colposcopy clinic for colposcopy due to lsil or hsil findings on a screening pap test. subjects with test results of ascus or asc-h will be excluded. a cervical cytology specimen will be taken from these subjects using both a spatula and a cytobrush, labeled with a deidentified code unique to the subject, and held under refrigeration pending microscopy in a manner identical to the second specimen processing described above. participants will then undergo colposcopy according to the standard of care based upon their prior cytology results.

Eligibility criteria:
inclusion criteria: * patients presenting for cervical cancer screening. * patients presenting for follow-up for positive cervical cancer screening. exclusion criteria: * patients who do not, or no longer, require cervical cancer screening

Keywords: screening ultraviolet microscope cervical dysplasia pap smear
the therapeutic efficacy of neurofeedback in depression

Conditions: Depression

Summary: the investigators examined the therapeutic efficacy of neurofeedback in depression subjects. the investigators hypothesize that 5 weeks neurofeedback training will be able to alleviate depressive symptoms.

subject * fulfilled dsm-iv criteria for depressive disorders. * persons who had organic disorders were excluded. * who had been treated by psychoactive drugs for at least 2 months prior to the study were excluded. design * subjects were randomly assigned to two groups (eeg biofeedback /psychotherapy placebo) by block randomization. * eeg biofeedback training was provided for 5 weeks(10 sessions, twice per week). each training session was composed of 6 four minute trials followed by 5 thirty second rest periods * psychotherapy placebo session was provided for 5 weeks. these sessions consisted of additional assessment, interpretation of the test results and providing information on course and treatment of mood disorder. * after subjects completed the training, they participated in a month-long (twice per week) self-training session to maintain a similar mental state during neurofeedback training sessions without feedback system's assistance. * subjects who had finished the psychotherapy placebo were referred to other therapists as necessary.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of mood disorder * right handed * current bdi-2 score exceed 10 exclusion criteria: * with psychotic symptom * with organic disorders * treated by psychoactive drugs for at least 2 months prior to the study * history of pathologic alcohol use

Keywords: depression biofeedback psychophysiology
acupuncture in the regulation of dai meridian for the metabolism of visceral adipose tissue in abdominal obese patients

Conditions: Abdominal Obesity; Metabolic Syndrome

Summary: to evaluate the effectiveness of acupuncture therapy combined with healthy education for patients with abdominal obesity.

this subject is a prospective, single-blind, parallel-group, randomized controlled clinical trial.120 patients with abdominal obesity are allocated into two groups with a ratio of 2:1.randomized series was generated by computer. the allocation was concealed. patients in the intervention group are received acupuncture therapy and healthy education. patients in the control group are only given healthy education. the treatment in both intervention group and control group lasts for 8 weeks. comparison of two groups of patients with abdominal fat thickness, fasting serum visfatin concentration, simple anthropometric parameters (including body weight, body mass index, waist circumference, hip circumference, waist-to-hip radio, waist-to-height radio, the percentage of body fat), fasting blood glucose, fasting insulin, glycosylated hemoglobin, fasting blood lipid (total cholesterol, triglyceride, high density lipoprotein, low density lipoprotein), uric acid, blood pressure, insulin resistance level, and obesity related lifestyle survey.

Eligibility criteria:
inclusion criteria: * met the diagnostic criteria of abdominal obesity (waist circumference of male ≥ 90cm, waist circumference of female ≥ 80cm); * ultrasound viscerofatty index ≥ 3; * age between 18-70 years old; * signed informed consent voluntarily. exclusion criteria: * secondary obesity caused by endocrine, hereditary, nervous system,or drugs; * within 3 months adjusted drug therapy for diabetes or hypertension or hyperlipidemia; * undergoing other therapies for reducing body mass and waist circumference, such as surgery, medication, etc; * participating or have participated in other studies; * pregnant or breast-feeding women; * critically ill, having hepatic-renal dysfunction or mental illness; * severe impairment in sight and hearing.
clinical trial to evaluate the efficacy and safety of 'pelubiprofen controlled released tab.' in acute traumatic injury

Conditions: Acute Traumatic Injury

Summary: a randomized, double-blind, placebo-controlled, parallel, multi-center phase iii clinical trial


Eligibility criteria:
inclusion criteria: * adult patient, ages over 19 years * patients with post traumatic acute pain within 48 hr(sprain/strain) * patient whose pain scale is over 50 mm(vas score) exclusion criteria: * patients with chronic pain * presence of a fracture or more than one injury * previous adverse reaction or known allergy to nsaids
extracorporeal low-intensity shockwave in diabetic nephropathy

Conditions: Diabetic Nephropathy Type 2

Summary: in the current study, we use extracorporeal low-intensity shockwave therapy (eswt) to treat on patients with type 2 diabetes in stage 3-4 chronic kidney disease and see whether it can improve the proteinuria, renal function, and blood pressure compared to baseline and control group.

diabetic nephropathy is the major contributor to end stage renal disease worldwide. extracorporeal shock wave treatments (eswt) with low-intensity was reported to be beneficial in inducing cell regeneration and reducing inflammation and have been successfully used for bone fracture, cardiac ischemia, and erectile disorders. in this study, sixty patients with stage iii \& iv (15\<=estimated glomerular filtration rate (egfr)\<60 ml/min/1.73m2) will be recruited and allocated to control and experimental groups in a 1:1 ratio. in experiment group, a total of 1200 shockwaves, with low energy density 0.1mj/mm2 and a frequency of 120 shocks/min, will be applied per kidney per treatment session. the treatment will be given twice a week for 3 consecutive weeks, followed by 3 weeks of recess and an additional series of 6 sessions (totally 12 times). patients in each group will be evaluated with egfr, urine protein-creatinine ration, blood pressure, and biochemistry data at the beginning (index day) and 12 months after starting of the therapy. (outcome time point: 12 months)

Eligibility criteria:
inclusion criteria: 1. age \>18 y/o or \<80 y/o 2. diagnosed as type 2 diabetes. 3. baseline hba1c \<7.5% 4. baseline glomerular filtration rate (egfr) ≧15 and \<60 ml/min/1.73m2 5. baseline urine albumin-to-creatinine ratio (uacr) \>30 and \<3000 mg/g 6. subject receives acei or arb for 3 months before enrollment 7. subject is willing to sign the permit and receive 12 times shockwave therapy exclusion criteria: 1. subject is pregnant or breast feeding 2. subject has cancer or chronic inflammatory disease 3. subject has bleeding tendency, eg thrombocytopenia, pt inr \> 2.5 4. subject has active urinary tract infection or other active infections 5. subject's sbp\>160mmhg or dbp\>100mmhg 6. subject has stroke, cardiac infection or arrhythmia in 6 months before enrollment 7. subject has local inflammation or infection over treatment areas 8. subject has pacemaker or other metal implants.

Keywords: diabetic nephropathies extracorporeal low intensity shockwave therapy proteinuria
enhancing gait using alternating-frequency dbs in parkinson disease

Conditions: Parkinson Disease; Gait Disorders, Neurologic; Disease Progression; Subthalamic Nucleus; Accidental Fall; Deep Brain Stimulation

Summary: the purpose of this study is to assess how alternating-frequency deep brain stimulation (dbs) works to improve postural instability and gait, while also treating other motor symptoms of parkinson disease (pd).

postural instability, gait impairment, and falls are among the greatest unmet needs in parkinson disease (pd). a single fall can be catastrophic, and impairments that limit mobility lead to social isolation or depression, and adversely affect bone and cardiovascular health. unfortunately, postural instability and gait disorders are refractory to current pharmacological and surgical treatments, including deep brain stimulation (dbs). this project will directly address this pressing need. we will recruit participants to perform a gait task, using a new, alternating dbs frequency paradigm, while body movements and neural signals are recorded. the findings will lead to improved therapies to address these symptoms in the future.

Eligibility criteria:
inclusion criteria: * bilateral stn dbs for pd * medtronic percept pc implanted dbs battery/pulse generator/recording system * presence of balance and/or walking impairment and/or freezing of gait * can walk without assistance, off meds, based on yes/no verbal response exclusion criteria: * severity of gait impairment should not require dependency to walker or cane * cannot tolerate monopolar stimulation at either of the two middle electrode contacts (prerequisite for the recording mode of the dbs) at high frequency (130 hz) or low frequency (60 hz). * concomitant conditions that may affect significantly the evaluation of balance or gait, including orthopedic, rheumatologic or other neurological diseases * contraindication to physical therapy * age \< 21 * diagnosis of dementia * not agreeable to having video taken of entire research visit

Keywords: postural instability gait impairment freezing of gait dbs frequency low alternating variable high
4-10 week observational study comparing 3 management strategies for obstructive chronic bronchopneumopathy (ocbp) in common clinical practice

Conditions: Obstructive Chronic BronchoPneumopathy (OCBP)

Summary: the management of patients with obstructive chronic bronchopneumopathy (ocbp) is based on a progression of therapeutic options and on a sensitization to physical activity. for these patients selected on ocbp stage 2, the treatment options include long acting beta-agonist bronchodilator (laba) or long acting muscarinic antagonist anticholinergic (lama) or both (lama+laba). the purpose of this study is to observe in common clinical practice the benefit of physical activity on quality of life, dyspnoea and walking distance for these patients under treatment (laba and/or lama) and to determine whether these 3 medical strategies (laba/lama/laba+lama) benefit from physical activity.


Eligibility criteria:
inclusion criteria: * patients with obstructive chronic bronchopneumopathy stage ≥ 2. * patients under treatment with laba or lama or laba+lama since at least 1 month. * vems/cvf\<70% * vems\<80% * patients without regular physical activity and without physical activity program since 1 year. exclusion criteria: * patients under treatment with laba + inhaled corticoids. * contraindication to physical activity. * patients with previous history of respiratory exacerbations.
bloodtranfusions after aortic surgery

Conditions: Hemorrhage; Thoracic Aneurysm

Summary: the purpose of this study is to answer the following question: leads a primary coagulation corrected with a single dose of fibrinogen concentrate after ascending aorta-arc reconstruction to a decrease in the number of allogenic blood transfusions, compared to placebo?

cardiothoracic surgery (ctc) is associated with blood loss and an increased risk for impaired coagulation by the use of a cbp. coagulation is a process of primary hemostasis by adhesion of trombocytes and aggregation, followed by secondary coagulation and fibrin formation. during ctc fibrinogen is the first coagulation factor which reaches critical concentration necessary for clotting. point of care clotting assay with thromboelastography (teg) provides qualitative information on coagulation factors and clot strength. specific coagulation factor correction of impaired clotting improves clot strength and may reduces the number of perioperative allogeneic blood transfusions, resulting in possible reduction of postoperative blood loss and reduction of the risk of re-operation in the short and long term. the hypothesis of this study is that a single dose fibrinogen concentrate immediately after ctc leads to a decrease in the number of allogenic blood transfusions in patients with clinically impaired clotting, verified by teg.

Eligibility criteria:
inclusion criteria: * elective surgery for thoracic aneurysm exclusion criteria: * prior trombosis or myocardial infarction, congenital coagulation disorder, use of anti-coagulants prior to surgery, prior thoracic surgery, pregnancy, pre-operative fibrinogen concentration \<1g/l
serological and urinary biomarkers in latin american patients with systemic lupus erythematosus: gladel 2.0 cohort

Conditions: Lupus Nephritis

Summary: lupus nephritis (ln) is one of the main manifestationsin sle patients, having an important impact on morbidity and mortality. renal biopsy is the "gold standard" for the diagnosis of ln, however, it is an invasive technique, not free of complications,which is not recommended to be performed serially as a follow-up tool for patients with ln. searching for biomarkers in sle has been the subject of interesting research, although results have not always been relevant. multiple biomarkers have been studied in different locations (soluble markers in blood, urine and biological fluids),of different nature(autoantibodies, genetic markers of "kidney damage") looking atdiagnostic and/orprognostic features. in recent years, several biomarkers have been developed that seek to find an association with pathological patterns, with pathogenic mechanisms and with a non-invasive diagnosis of different glomerulopathies, allowing the identification of prognostic subgroups in each type of kidney disease, while predicting response to treatment and/or recurrence. to date, double-stranded anti-dna antibodies (anti-dsdna) and serum complement are the only non-invasive routine biomarkers for monitoring renal activity in patients with ln. however, these markers are only the reflection of the immune activity of the disease and they are not markers of renal damage or poor prognosis. for all the above, the purpose of this study is, in a case-control study, to evaluate simultaneously serum (ana, anti-dsdna, anti-c1q, anti-cardiolipin igg and igm, anti-ß2gpi igg and igm, anti-phosphatidylserine/prothrombin antibodies, and anti-dfs70 antibodies) and urinary biomarkers, and the presence of anti-dfs70 antibodies, in a multiethnic cohort of patients with sle such as the cohort of gladel, and assess its possible correlation with various socio-demographic, clinical and serological manifestations of the disease. in subgroup of patients, transcriptome studies will be performed using rna from blood and tissue to identify possible transcriptional signatures.


Eligibility criteria:
inclusion criteria: * consecutive patients with a diagnosis of sle will be included. patients should meet at least one ofthe classification criteria: acr 1982/1997 (1) and/or slicc 2012 (2) to determine the efficacy of calcineurin inhibitor-containing treatment regimens in ln cohorts by ethnic groups. * age ≥18 years old. * patients and controls that volunteer toparticipate and sign the informed consent exclusion criteria: * patients with other systemic autoimmune diseases or overlap syndrome (rheumatoid arthritis, systemic sclerosis, dermatomyositis, systemic vasculitis and others). * patients who have urinary infection, pregnancy or have a history of hepatitis b, c or hiv virus infection. * those patients presenting with antiphospholipid syndrome (aps) associated with lupus will not be excluded from the study.